Search
Ciluprevir
go.drugbank.com/drugs/DB05868InvestigationalThe compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.
Azintuxizumab vedotin
go.drugbank.com/drugs/DB14847InvestigationalHas Come Back or Had No Response to Recent Cancer Treatment). … Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer
FT-1101
go.drugbank.com/drugs/DB17553Investigational[A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Hexobendine
go.drugbank.com/drugs/DB13265ApprovedIt has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478].
Nigella sativa oil
go.drugbank.com/drugs/DB28165InvestigationalNigella Sativa Oil is under investigation in clinical trial NCT06823544 (A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis
Zotiraciclib
go.drugbank.com/drugs/DB16656InvestigationalZotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide
Cardarine
go.drugbank.com/drugs/DB05416InvestigationalCardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease. … Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia.
Lexibulin
go.drugbank.com/drugs/DB05147InvestigationalCYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias
INCB-9471
go.drugbank.com/drugs/DB12960InvestigationalINCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalThe plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA. … MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.